Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open label, balanced, randomised, two-treatment, two-period,
two-sequence, single-dose crossover bioavailability study on fenofibrate formulations
comparing fenofibrate 160 mg tablets of Ranbaxy Laboratories with Tricor 160 mg tablets in
healthy, adult, human subjects under fasting conditions.